Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: cruncher who wrote (548)	5/9/1998 10:31:00 PM
From: Luke	Respond to of 1906

Hi. Interesting medline abstract from Cell by Amgen. Anybody know about or have any comments about this project? Has this been discussed anywhere? Title Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments Author Simonet WS; Lacey DL; Dunstan CR; Kelley M; Chang MS; L uthy R; Nguyen HQ; Wooden S; Bennett L; Boone T; Shimamoto G; DeRose M; Elliott R; Colombero A; Tan HL; Trail G; Sullivan J; Davy E; Bucay N; Renshaw-Gegg L; Hughes TM; Hill D; Pattison W; Campbell P; Boyle WJ; et al Address Department of Molecular Genetics' Amgen Inc.' Thousand Oaks' California 91320' USA. Source Cell, 89(2):309-19 1997 Apr 18 Abstract A novel secreted glycoprotein that regulates bone resorption has been identified. The protein' termed Osteoprotegerin (OPG)' is a novel member of the TNF receptor superfamily. In vivo' hepatic expression of OPG in transgenic mice results in a profound yet nonlethal osteopetrosis' coincident with a decrease in later stages of osteoclast differentiation. These same effects are observed upon administration of recombinant OPG into normal mice. In vitro' osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by recombinant OPG. Furthermore' OPG blocks ovariectomy-associated bone loss in rats. These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.